De Souza was previously president and CEO of Synaptic Pharmaceuticals, president and CEO of Archemix Corp., co-founder and chief scientific officer of Neurocrine Biosciences, senior vice president at Aventis and director of CNS diseases research at DuPont Merck

No CEO replacement was named, but the firm said Mel Bridges and John Chiplin both will move to executive director roles within the company...Karo Bio AB, of Stockholm, Sweden, appointed Fredrik Lindgren as CEO and president, succeeding Per Olof Wallström, who has resigned and is leaving the company

Catalyst Biosciences Inc., of South San Francisco, named William J. Dawson chief financial officer. Garnet BioTherapeutics Inc., of Malvern, Pa., appointed Sanjay Batra senior vice president of development. NeoStem Inc., of New York, appointed Mariusz Ratajczak to its scientific advisory board. Orexigen Therapeutics Inc., of San Diego, appointed Peter K. Honig to its board. PharmaNet Development Group Inc., of Princeton, N.J., named George A. McMillan chief financial officer. Transdel

AspenBio Pharma Inc., of Castle Rock, Colo., has appointed Steve Lundy CEO and a member of its board...IGEN Networks Corp., of Las Vegas, appointed Monty Ormsby president and Michael Grudman chief financial officer and secretary

CEO Appointments: Action Pharma, of Holte, Denmark, has appointed Ingelise Saunders as CEO...Before joining Action she was president and CEO of ACE BioSciences for five years, and prior to that was CEO of Celltech Pharmaceuticals Plc...as vice president of worldwide licensing and external research and vice president of basic research

Tekmira Pharmaceuticals Corp., of Vancouver, British Columbia, appointed Daniel Kisner chairman and named Kenneth Galbraith and Frank Karbe to its board...Trevena Inc., of King of Prussia, Pa., named David Soergel vice president and head of clinical development

to vice president of financing and administration...Pepscan Therapeutics, of Lelystad, the Netherlands, named Peter Timmerman chief technology officer and appointed Klaus Schwamborn chief development officer

IPierian Inc., of South San Francisco, appointed Michael C. Venuti president and chief scientific officer...King Pharmaceuticals Inc., of Bristol, Tenn., appointed Kevin S. Crutchfield and Derace Lan Schaffer to its board...Onyx Pharmaceuticals Inc., of Emeryville, Calif., appointed Ted W. Love executive vice president and head of R&D

VaxInnate Corp., of Cranbury, N.J., named Thomas Hofstaetter president and CEO, and Alan Shaw, who previously held that position, has assumed the newly created role of chief scientific officer and becomes board chairman

Cephalon Inc., of Frazer, Pa., promoted Kevin Buchi to chief operating officer, Wilco Groenhuysen to executive vice president and chief financial officer and Alain Aragues to executive vice president of Cephalon Europe

Tom Amick will serve as president and CEO, while Edward L. Field was named executive vice president and chief business officer...Banyan Biomarkers Inc., of Alachua, Fla., appointed Jackson Streeter CEO and chief medical officer

Oxford Immunotec Ltd., of Oxford, UK, elected Peter Klemm nonexecutive director and named Frank Vandeputte vice president of sales and marketing...YM BioSciences Inc., of Mississauga, Ontario, added Rogerio C. Lilenbaum and Minesh Mehta to its U.S

Diffusion Pharmaceuticals LLC, of Charlottesville, Va., named David R. Jones chief medical officer and member of its scientific advisory board...GeoVax Labs Inc., of Atlanta, appointed Mark J. Newman vice president of research and development...ImmuCell Corp., of Portland, Maine, added Bobbi Jo Kunde as director of sales and marketing

BIND Biosciences Inc., of Cambridge, Mass., appointed Scott Minick president and CEO...Cel-Sci Corp., of Vienna, Va., appointed Todd S. Burkhart vice president of manufacturing/facilities and commercial operations...CrystalGenomics Inc., of Seoul, South Korea, and CG Pharmaceuticals Inc., of Emeryville, Calif., appointed Eric M. Nelson vice president of business development

operations, Karen Hodgkin head of clinical development and Tina Crombie head of business administration...ConvaTec, of Paris, named Erik Zimmer vice president and general manager within its European, Middle East and Africa region...Sequenom Inc., of San Diego, appointed Kenneth Buechler and David Pendarvis to its board of directors

Senesco Technologies Inc., of New Brunswick, N.J., appointed Jack Van Hulst president and CEO...Siriuis Genomics, of Vancouver, British Columbia, appointed Chris Wagner president and CEO...UCB SA, of Brussels, Belgium, named Ismail Kola executive vice president of UCB and president of UCB New Medicines

Anesiva Inc., of South San Francisco, named Ted W. Love and David C. U'Prichard to its board, following completion of the merger with Arcion Therapeutics...CellCyte Genetics Corp., of Eastgate, Wash., appointed Douglas Cerretti chief science officer and director of business development...It also appointed Andrew K. W. Powell executive vice president, general counsel and secretary

Oxygen Biotherapeutics Inc., of Durham, N.C., added Rene A. Eckert and William A. Chatfield to its board...Santaris Pharma A/S, of Horsholm, Denmark, added Mark Wedel as vice president and chief medical officer and Stuart Mackey as vice president of strategy and chief business officer

BioAlliance Pharma SA, of Paris, appointed André Ulmann and Denis Biju-Duval to its supervisory board...BrainCells Inc., of San Diego, appointed Edward Scolnick and David Holtzman to its scientific advisory board...DBV Technologies, of Paris, added Gideon Lack and Philippe Eigenmann to its scientific advisory board